4BIO Capital

Cytospire Therapeutics is a biopharmaceutical company focused on developing innovative therapies.

Ray Therapeutics is a clinical-stage biotechnology company developing best-in-class vision restoration therapies for people with degenerative retinal diseases independent of genetic mutation, utilizing optogenetics technology.

SparingVision is a clinical-stage genomic medicines company focused on developing innovative treatments for ocular diseases, particularly inherited retinal diseases (IRDs) such as Retinitis Pigmentosa and age-related macular degeneration. The company aims to move beyond single gene correction therapies to provide mutation-independent treatments.

Araris Biotech AG is pioneering the development of a novel, proprietary antibody-drug conjugate (ADC)-linker technology that enables the attachment of payloads to 'off-the-shelf' antibodies in one step, resulting in highly homogenous, stable, and potent ADC therapies for targeted cancer treatment.

ADC Therapeutics is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs) advancing proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies.

Developing CAR T cell therapies for patients with cancer and autoimmune diseases.

uniQure is a global leader in gene therapy, delivering innovative cures that transform lives through an AAV-based technology platform. The company focuses on treating serious unmet medical needs, particularly in genetic disorders such as Huntington's disease and hemophilia B.

Entact Bio is pioneering precision medicines that enhance the function of beneficial proteins, targeting previously undruggable pathways and addressing hard-to-treat genetic disorders.

5AM Ventures focuses exclusively on the earliest stages of life sciences companies, often investing at or before seed stage and operating an in-house company-creation engine called the 4:59 Initiative. The firm combines hands-on involvement with partners taking short-term operating roles and remaining deeply engaged throughout a company's life, alongside systematic focus on capital efficiency and faster realizations.

ARCH Venture Partners invests at the concept stage, co-founding and building breakthrough life sciences and deep-science platforms directly with university researchers, acting as a company-builder partner to commercialize frontier biology. The firm concentrates its capital on breakthrough life sciences and deep science platforms with a stated mission to catalyze discoveries that prevent, detect, and cure disease.

Early-stage drug-discovery company creator that originates companies in-house, incubates single ultra-orphan and rare-disease bets for years and millions, and commits to very long development timelines.

Seed and early-stage investor that creates and invests in biotech startup companies, emphasizing company creation.

Fellowship for early-career scientists run by repeat deep-tech founders, prioritizing technical founder quality, for those who've never written business plans, offering up to $1M and not taking IP rights. SciFounders is run by repeat deep-tech founders who previously built Mammoth Biosciences and Conception. The fund is designed for scientists who have never written a business plan and focuses on technical founder quality over trendy ideas, operating as a long-term partner rather than a fixed-cohort program with no formal end date.